Talarozole

DB13083InvestigationalSmall molecule

Talarozole has been investigated for the treatment of Psoriasis and Cutaneous Inflammation.

Mechanism: Rambazole is a new generation all-trans retinoic acid metabolism blocking agent, highly specific against the retinoic acid 4-hydroxylase. The drug alleviates hyperproliferation and normalizes differentiation of the epidermis in animal models of psoriasis. All-trans-retinoic acid (RA) regulates epithelial differentiation and growth through activation of specific nuclear RA receptors (RARs). Rambazole acts by inhibiting the metabolic breakdown of the retinoid, increasing the biological efficacy of RA.
Curator reviewed
Formula / weight: C₂₁H₂₃N₅S · 377.51 g/mol (avg)

Resolves to

Compound

Structure

InChIKeySNFYYXUGUBUECJ-UHFFFAOYSA-NSMILESCCC(CC)C(N1C=NC=N1)C1=CC=C(NC2=NC3=CC=CC=C3S2)C=C1

Targets

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Talarozole, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.